ContractMaster Formulation Development Agreement • May 5th, 2020 • Delaware
EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. Execution Copy AMENDED AND RESTATED MASTER FORMULATION DEVELOPMENT AGREEMENT This Amended and Restated Master Formulation Development Agreement (the “Agreement”), dated June 30, 2017 (the “Amendment and Restatement Effective Date”), is made by and between Oakwood Laboratories, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 (“Oakwood”), and Edge Therapeutics, Inc., a New Jersey corporation having an address of 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 (“Edge”). Edge and Oakwood are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Recitals Whereas, Edge is engaged in the development of polymer-based sustained-release injectable drug products; Whereas, Oakwood is engaged in the lice
ContractMaster Formulation Development Agreement • May 5th, 2020 • Delaware
EX-10.3 2 ex10_3.htm EXHIBIT 10.3 EXHIBIT 10.3 CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. MASTER FORMULATION DEVELOPMENT AGREEMENT THIS MASTER FORMULATION DEVELOPMENT AGREEMENT (the "Agreement'') is entered into as of March 12, 2015 (the "Effective Date' ') by and between OAKWOOD LABORATORIES, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146, USA ("Oakwood''),and Edge Therapeutics, Inc., a New Jersey corporation having an address of 200 Connell Drive Suite 1600 Berkeley Heights, NJ 07922 ("Edge''). RECITALS WHEREAS, Edge is engaged in the development of polymer-based sustained-release injectable drug products; WHEREAS, Oakwood is engaged in the licensing, development and manufacture of injectable sustained release formulations for new chemical entities; WHEREAS, Edge desires to engage Oakwood to provide Edge with drug formula
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS.Master Formulation Development Agreement • March 8th, 2016 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS MASTER FORMULATION DEVELOPMENT AGREEMENT (the "Agreement'') is entered into as of March 12, 2015 (the "Effective Date' ') by and between OAKWOOD LABORATORIES, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146, USA ("Oakwood''),and Edge Therapeutics, Inc., a New Jersey corporation having an address of 200 Connell Drive Suite 1600 Berkeley Heights, NJ 07922 ("Edge'').
